Transglutaminase 2 inhibitors and their therapeutic role in disease states.
about
Transglutaminase 2 undergoes a large conformational change upon activationSerotonylation of vascular proteins important to contractionCeliac disease: prevalence, diagnosis, pathogenesis and treatmentThe interaction of angiocidin with tissue transglutaminaseInterferon-γ activates transglutaminase 2 via a phosphatidylinositol-3-kinase-dependent pathway: implications for celiac sprue therapyTransglutaminase is a tumor cell and cancer stem cell survival factorTransglutaminase is a therapeutic target for oxidative stress, excitotoxicity and stroke: a new epigenetic kid on the CNS blockCurrent and emerging therapy for celiac diseaseTransglutaminase 2-mediated serotonylation in pulmonary hypertensionThe redox state of transglutaminase 2 controls arterial remodelingCellular functions of tissue transglutaminaseRole of transglutaminase 2 in celiac disease pathogenesisActivation and inhibition of transglutaminase 2 in miceClinical and biological significance of tissue transglutaminase in ovarian carcinoma.Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury.Parallels between pathogens and gluten peptides in celiac sprueTransamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.Tissue transglutaminase contributes to the pathogenesis of preeclampsia and stabilizes placental angiotensin receptor type 1 by ubiquitination-preventing isopeptide modification.Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease.Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules.Bcr is a substrate for Transglutaminase 2 cross-linking activity.TGM2: a cell surface marker in esophageal adenocarcinomas.Transglutaminase 2 expression is increased as a function of malignancy grade and negatively regulates cell growth in meningioma.Transglutaminase 2 exacerbates α-synuclein toxicity in mice and yeastPrevention measures and exploratory pharmacological treatments of celiac disease.An in vivo tagging method reveals that Ras undergoes sustained activation upon transglutaminase-mediated protein serotonylation.Simultaneously targeting tissue transglutaminase and kidney type glutaminase sensitizes cancer cells to acid toxicity and offers new opportunities for therapeutic interventionNovel 3-arylethynyl-substituted thieno[3,4-b]pyrazine derivatives as human transglutaminase 2 inhibitors.Transglutaminase 2 and its role in pulmonary fibrosis.TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2/serpinB2 and transglutaminase 2.Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.Implication for transglutaminase 2-mediated activation of β-catenin signaling in neointimal vascular smooth muscle cells in chronic cardiac allograft rejectionTissue transglutaminase: a new target to reverse cancer drug resistanceRegulation of the activities of the mammalian transglutaminase family of enzymes.Transglutaminase 2 cross-linking activity is linked to invadopodia formation and cartilage breakdown in arthritis.Emerging therapeutic options for celiac disease: potential alternatives to a gluten-free diet.The transglutaminase type 2 and pyruvate kinase isoenzyme M2 interplay in autophagy regulation.Elevated Transglutaminase Activity Triggers Angiotensin Receptor Activating Autoantibody Production and Pathophysiology of Preeclampsia.The Different Conformational States of Tissue Transglutaminase Have Opposing Affects on Cell Viability.
P2860
Q21092747-D8BBE72B-F18B-48B9-B759-BDF140C75630Q21562428-2013C6D8-F7A1-4F2F-810F-B8FFCA0AE48AQ22305490-EBD84F98-5E9D-4808-8959-2F479815289DQ24318943-63BC66AF-B913-4AC1-AD28-FF78B2313ECAQ24611233-F2B3F6A7-CBA4-47B9-BC3A-BCF636CF5EF6Q26799862-B71F03C7-F26B-44A5-85F1-B65FAE8AEA60Q26824549-0E4FAADB-9DB3-4BF7-9190-2AD594343B66Q27014843-12010F05-F114-4FA0-987F-F9F7AD048840Q27027862-01BED9DA-BBF8-45B1-89E6-477D4CCE1522Q27325795-8EA152B3-166B-4293-B1AF-F07E4999EB08Q28260600-681D24D8-5C21-485B-8BD8-CA1E6D56CAC7Q28262529-8F8A6F09-091A-4C4C-B9BD-AEE8F5BEC314Q28480486-754A06A1-96EE-43AB-89F8-65CC1EE0BC85Q30483685-47D82D67-E2A5-4749-BA75-90591AF1B767Q33325485-4FDAC55B-515A-4D8C-885A-2662E8D50F48Q33329537-69975BF6-4B05-45F3-8F15-D03B48B0AB0EQ33728989-AD9976E1-B738-46A0-87AE-AEC4DB5AD346Q33737470-A40234D0-0EA8-4CA6-8EDD-739523E55FE0Q33793353-EC8F5CAB-A1DB-44BE-8BB8-3E2D2F56D560Q33799573-46785F86-4EA1-41FD-A2DF-909A03E3399EQ33817561-A1C599BB-23BC-461C-A0A1-D1D926D076BFQ34219975-CD0326F4-618D-473A-BE7A-2E799C39BF3FQ34233236-A698E7CC-2032-473F-A105-9B51EE372558Q34365610-5BDCCBB6-11E7-4032-BB1C-B5A4668FA4C4Q34623902-F1D8CA97-47A6-4805-A3FC-067B19F54FAEQ34671606-650DC394-B34D-40A9-80F6-EFACA1B5E45EQ34927039-4787EA7D-9902-43E6-B7AA-C74F55FB84C8Q35176934-40B04B9B-3597-4C9A-83C1-16BE2B95BF14Q35527871-045F9E4B-6E2B-4780-A971-0ACC8C200973Q35708946-8DBFF811-E4D8-4266-B1B1-12CE797BE821Q35858675-2A9649B6-217E-40BC-AB01-F1C6EB24E34EQ36393086-0D53156B-011F-45A9-84A2-32AF452560F1Q36432923-E06C9AE6-129B-4072-B220-5EE0E4271053Q36503511-CF4C0BC0-F22D-47DF-81E2-630ECF88FA48Q36620140-BE1B1EC5-ED0A-4BBD-AC29-6C28B6C447C2Q36633284-9D0439C1-1578-43E7-9421-ABF76CAC2AF6Q36676716-E6F0E57A-3069-4F15-A87B-9B17E8C77F2EQ36689128-1A05E304-A2BE-4567-BD89-333C12CC0117Q36836373-CF86C670-4320-4971-8C44-E49F7C9CADF9Q36884822-5073A720-E00F-4F5A-B278-A6EA53B8E6CF
P2860
Transglutaminase 2 inhibitors and their therapeutic role in disease states.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Transglutaminase 2 inhibitors and their therapeutic role in disease states.
@ast
Transglutaminase 2 inhibitors and their therapeutic role in disease states.
@en
type
label
Transglutaminase 2 inhibitors and their therapeutic role in disease states.
@ast
Transglutaminase 2 inhibitors and their therapeutic role in disease states.
@en
prefLabel
Transglutaminase 2 inhibitors and their therapeutic role in disease states.
@ast
Transglutaminase 2 inhibitors and their therapeutic role in disease states.
@en
P2860
P1476
Transglutaminase 2 inhibitors and their therapeutic role in disease states.
@en
P2093
Chaitan Khosla
Matthew Siegel
P2860
P304
P356
10.1016/J.PHARMTHERA.2007.05.003
P577
2007-05-13T00:00:00Z